Skip to main content
TipRanks
Go Ultimate75% OFF

PDS Biotechnology (EU6) AI Stock Analysis

2 Followers
DE:EU6

PDS Biotechnology

(Frankfurt:EU6)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Clinical validation of PDS0301PDS0301 has generated encouraging Phase 2 outcomes in difficult-to-treat metastatic colorectal cancer, supporting its potential differentiation in a large unmet-need population. The planned registrational Phase 3 protocol creates a defined path toward a more commercially meaningful development stage.
Negative Factors
Persistent pre-revenue lossesPDS Biotechnology remains pre-revenue and deeply loss-making, with no demonstrated commercial revenue base to offset research and development costs. Until a candidate is approved or partnered on meaningful terms, earnings power remains dependent on future clinical success and continued access to capital.

PDS Biotechnology (EU6) vs. iShares MSCI Germany ETF (EWG)

-100%-50%0%50%100%150%DE:EU6+7.10%EWG+1.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 43.39M
Dividend Yield
―
Average Volume (3M)
8,848
Price to Earnings (P/E)
-1.4
Beta (1Y)
0.64
Revenue Growth
―
EPS Growth
35.78%
Country
Germany
Employees
21
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

PDS Biotechnology Business Overview & Revenue Model

Company Description

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical tria...

PDS Biotechnology Earnings Call Summary

Earnings Call Date:May 13, 2026(Q1-2026)|% Change Since:-38.58%|Next Earnings Date:May 11, 2022
Earnings Call SentimentPositive

The call conveyed meaningful clinical and intellectual property progress: a strategic protocol amendment for VERSATILE-003 that reduces patient count (~28.6%) and time to an interim readout, peer-reviewed and encouraging clinical data for PDS01ADC, strengthened IP extending PDS0101 protection into the 2040s, and established manufacturing processes. Financially, operating expenses and net loss improved year-over-year. Key risks include a relatively modest cash balance ($21.7M), continued unprofitability with rising interest expense, the need for OS data for full approval and additional confirmatory trials, and competition in the HPV16 head and neck space. On balance, the operational and clinical positives outweigh the near-term financial and development risks.

Positive Updates

Protocol amendment for VERSATILE-003 to enable faster path to approval
Amended trial to add progression-free survival (PFS) as an interim co-primary endpoint while retaining overall survival (OS) for full approval; randomization changed from 2:1 to 1:1 and planned enrollment reduced from ~350 to ~250 patients (≈28.6% reduction), expected to shorten duration and lower trial costs and time to an interim readout.

Negative Updates

Cash balance and potential runway considerations
Cash on hand was $21.7M as of March 31, 2026; management did not provide explicit runway or guidance on financing needs, which could raise near-term funding questions given ongoing late-stage and development activities.

Company Guidance

Management guided that the VERSATILE‑003 amendment adopts progression‑free survival as an interim co‑primary endpoint (retaining overall survival for full approval) to enable a potential accelerated approval, changes randomization from 2:1 to 1:1 and reduces planned enrollment from ~350 to ~250 patients to shorten duration, lower external and internal costs and speed an interim readout (sites remained engaged and enrollment is restarting); they reiterated PDS0101’s differentiators (only late‑stage HPV16 HNSCC regimen that is subcutaneous and requires just five doses) and noted new U.S. and Japanese patents extending PDS0101 market protection into the 2040s. Financial metrics include cash of $21.7M as of March 31, 2026, a Q1 net loss of ~$7.3M ($0.13 per share) versus $8.5M ($0.21) year‑ago, R&D of $3.5M (vs $5.8M), G&A of $3.1M (vs $3.3M), total operating expenses of $6.5M (vs $9.1M) and net interest expense of $0.8M (vs $0.6M); operational guidance also highlighted an established Versamune manufacturing process with CMC validation/scale‑up ahead of a BLA and that PDS01ADC data (JCO Oncology Advances, NCI/AACR) support advancement—colorectal Stage 2 is fully enrolled with additional data expected by year‑end.

PDS Biotechnology Risk Analysis

PDS Biotechnology disclosed 52 risk factors in its most recent earnings report. PDS Biotechnology reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

PDS Biotechnology Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:EU6 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
LTRNLTRN40Underperform$4.51M-0.21-674.37%――32.93%
CALCCALC39Underperform$8.07M-0.28-3029.57%――45.29%
SNTISNTI39Underperform$7.25M-0.043547.64%――56.67%
TPSTTPST38Underperform$6.12M-0.07-3552.74%――61.31%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:EU6TPSTLTRNCALCSNTIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:EU6 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:EU6Pds Biotechnology0.690.046.28%
TPSTTempest Therapeutics, Inc.0.29-3.88-93.12%
LTRNLantern Pharma, Inc.0.24-3.13-92.73%
CALCCalcimedica, Inc.1.26-19.69-93.99%
SNTISenti Biosciences, Inc.1.77-67.20-97.43%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.